PE20190394A1 - ANTI-C5 ANTIBODIES AND METHODS OF USE - Google Patents

ANTI-C5 ANTIBODIES AND METHODS OF USE

Info

Publication number
PE20190394A1
PE20190394A1 PE2018003148A PE2018003148A PE20190394A1 PE 20190394 A1 PE20190394 A1 PE 20190394A1 PE 2018003148 A PE2018003148 A PE 2018003148A PE 2018003148 A PE2018003148 A PE 2018003148A PE 20190394 A1 PE20190394 A1 PE 20190394A1
Authority
PE
Peru
Prior art keywords
seq
antibody
binds
affinity
substitution
Prior art date
Application number
PE2018003148A
Other languages
Spanish (es)
Inventor
Yoshinao Ruike
Zenjiro Sampei
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of PE20190394A1 publication Critical patent/PE20190394A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Referido a un anticuerpo que se une a C5, anti-C5, caracterizado porque se une a un epitopo dentro de la cadena beta de C5 con una afinidad mas alta a pH neutro que a pH acido. Este anticuerpo se caracteriza por que entra en contacto con los aminoacidos D51 y K109 de C5 (SEC ID NO:39); la afinidad del anticuerpo por C5 (SEC ID NO:39) es mayor que la afinidad del anticuerpo por un mutante C5 que consiste en una sustitucion E48A de la SEC ID NO: 39; y se une a una proteina C5 que consiste en la secuencia de aminoacidos de la SEC ID NO: 40 a pH 7.4, pero no se une a una proteina C5 que consiste en la secuencia de aminoacidos de la SEC ID NO: 39 con una sustitucion de H72Y a pH 7.4. Tambien se refiere a un metodo para producir el citado anticuerpo.Refers to an antibody that binds to C5, anti-C5, characterized in that it binds to an epitope within the beta chain of C5 with a higher affinity at neutral pH than at acidic pH. This antibody is characterized in that it comes into contact with amino acids D51 and K109 of C5 (SEQ ID NO: 39); the affinity of the antibody for C5 (SEQ ID NO: 39) is greater than the affinity of the antibody for a C5 mutant consisting of an E48A substitution of SEQ ID NO: 39; and binds to a C5 protein consisting of the amino acid sequence of SEQ ID NO: 40 at pH 7.4, but does not bind to a C5 protein consisting of the amino acid sequence of SEQ ID NO: 39 with a substitution of H72Y at pH 7.4. It also refers to a method of producing said antibody.

PE2018003148A 2016-06-17 2017-06-16 ANTI-C5 ANTIBODIES AND METHODS OF USE PE20190394A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2016120325 2016-06-17

Publications (1)

Publication Number Publication Date
PE20190394A1 true PE20190394A1 (en) 2019-03-13

Family

ID=59969459

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2023002969A PE20240825A1 (en) 2016-06-17 2017-06-16 ANTI-C5 ANTIBODIES AND METHODS OF USE
PE2018003148A PE20190394A1 (en) 2016-06-17 2017-06-16 ANTI-C5 ANTIBODIES AND METHODS OF USE

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2023002969A PE20240825A1 (en) 2016-06-17 2017-06-16 ANTI-C5 ANTIBODIES AND METHODS OF USE

Country Status (19)

Country Link
EP (1) EP3472316A4 (en)
JP (3) JP6202774B1 (en)
KR (2) KR101852739B1 (en)
CN (3) CN109312326B (en)
AU (1) AU2017285763B2 (en)
BR (1) BR112018075688A2 (en)
CA (1) CA3021956A1 (en)
CL (1) CL2018003573A1 (en)
CR (1) CR20190013A (en)
EA (1) EA201990018A1 (en)
IL (2) IL300611A (en)
MX (2) MX2018015030A (en)
MY (1) MY187848A (en)
PE (2) PE20240825A1 (en)
PH (1) PH12018502354A1 (en)
SG (2) SG10201800265UA (en)
TW (4) TWI789369B (en)
UA (1) UA126561C2 (en)
WO (1) WO2017217524A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4342995A3 (en) 2006-03-31 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
EP3056513A1 (en) 2008-04-11 2016-08-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
RU2658504C9 (en) 2010-11-30 2018-08-21 Чугаи Сейяку Кабусики Кайся Antigen-binding molecule, that is capable of multiple binding with a lot of antigenic molecules
TW201809008A (en) 2014-12-19 2018-03-16 日商中外製藥股份有限公司 Anti-C5 antibodies and methods of use
KR102534895B1 (en) 2016-06-14 2023-05-24 리제너론 파아마슈티컬스, 인크. Anti-C5 Antibodies and Uses Thereof
CN109312326B (en) * 2016-06-17 2022-09-09 中外制药株式会社 anti-C5 antibodies and methods of use
TW202300168A (en) 2016-08-05 2023-01-01 日商中外製藥股份有限公司 Composition for prophylaxis or treatment of il-8 related diseases
EP3692064A1 (en) * 2017-10-04 2020-08-12 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis
AU2018383751A1 (en) 2017-12-13 2020-06-25 Regeneron Pharmaceuticals, Inc. Anti-C5 antibody combinations and uses thereof
JP2021536509A (en) * 2018-09-06 2021-12-27 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Humanized anti-C5 antibody and its use
AU2020261073A1 (en) * 2019-04-24 2021-12-16 Kira Pharmaceuticals (Us) Llc Bi-functional humanized anti-C5 antibodies and factor H fusion proteins and uses thereof
CN113563467A (en) * 2020-04-28 2021-10-29 上海普铭生物科技有限公司 Antibodies against human complement protein C5 and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0230985Y2 (en) 1985-07-08 1990-08-21
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
JP4643139B2 (en) 2001-06-12 2011-03-02 テレフオンアクチーボラゲット エル エム エリクソン(パブル) Synchronization in the UMTS Terrestrial Radio Access Network (UTRAN)
US7432356B2 (en) 2001-08-17 2008-10-07 Genentech, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
JP4333939B2 (en) 2001-08-27 2009-09-16 ロード・コーポレーション Trolley wire suspension system
DE10253331A1 (en) 2002-11-14 2004-06-03 Symrise Gmbh & Co. Kg Use of trans-pellitori as a flavoring
US7267849B2 (en) 2004-03-02 2007-09-11 Nitto Denko Corporation Compensator for liquid crystal display
KR20080069889A (en) 2007-03-20 2008-07-29 (주)화도 Pe pipe
WO2008113834A2 (en) * 2007-03-22 2008-09-25 Novartis Ag C5 antigens and uses thereof
US8420298B2 (en) 2007-04-11 2013-04-16 Sekisui Chemical Co., Ltd. Method for production of crosslinked polyvinyl acetal resin, and crosslinked polyvinyl acetal resin
EP3056513A1 (en) * 2008-04-11 2016-08-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
EP2328616B1 (en) * 2008-08-05 2015-04-29 Novartis AG Compositions and methods for antibodies against complement protein c5
KR20100054403A (en) 2008-11-14 2010-05-25 삼성전자주식회사 Online composition apparatus and method for writing by multiple participants
TW201206466A (en) * 2010-03-11 2012-02-16 Rinat Neuroscience Corp Antibodies with pH dependent antigen binding
BR112012022917A2 (en) * 2010-03-11 2017-01-10 Pfizer ph-dependent antigen binding antibodies
KR20110111007A (en) 2010-04-02 2011-10-10 이화여자대학교 산학협력단 Octahydro-binaphthol derivatives for l/d optical conversion and optical resolution
KR20110122011A (en) 2010-05-03 2011-11-09 황보철종 System for administrating combine store point and method therefor
WO2014028354A1 (en) * 2012-08-13 2014-02-20 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 antibodies with ph-dependent binding characteristics
US10280215B2 (en) * 2013-01-31 2019-05-07 Seoul National University R&Db Foundation Anti-C5 antibodies and methods of treating complement-related diseases
EP2978451B1 (en) * 2013-03-29 2019-11-27 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
NZ631007A (en) * 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
TW201809008A (en) * 2014-12-19 2018-03-16 日商中外製藥股份有限公司 Anti-C5 antibodies and methods of use
CA3005592C (en) * 2015-12-18 2024-01-23 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use
CN109312326B (en) * 2016-06-17 2022-09-09 中外制药株式会社 anti-C5 antibodies and methods of use

Also Published As

Publication number Publication date
TW201809000A (en) 2018-03-16
TWI789369B (en) 2023-01-11
TW202337903A (en) 2023-10-01
BR112018075688A2 (en) 2019-04-02
UA126561C2 (en) 2022-11-02
JP2018009021A (en) 2018-01-18
CN109312326B (en) 2022-09-09
MY187848A (en) 2021-10-26
RU2019100222A (en) 2020-07-17
RU2019100222A3 (en) 2020-11-05
AU2017285763B2 (en) 2024-02-01
CA3021956A1 (en) 2017-12-21
PH12018502354A1 (en) 2019-09-23
CN115925922A (en) 2023-04-07
EP3472316A1 (en) 2019-04-24
AU2017285763A1 (en) 2018-11-08
EP3472316A4 (en) 2020-01-08
JP7032077B2 (en) 2022-03-08
TWI610941B (en) 2018-01-11
MX2018015030A (en) 2019-04-22
TW201808996A (en) 2018-03-16
WO2017217524A1 (en) 2017-12-21
TW202239766A (en) 2022-10-16
CR20190013A (en) 2019-03-05
IL300611A (en) 2023-04-01
KR102226975B1 (en) 2021-03-11
CL2018003573A1 (en) 2019-02-01
PE20240825A1 (en) 2024-04-18
EA201990018A1 (en) 2019-08-30
KR101852739B1 (en) 2018-04-30
JP6202774B1 (en) 2017-09-27
CN115960223A (en) 2023-04-14
MX2023001360A (en) 2023-02-27
CN109312326A (en) 2019-02-05
IL263657A (en) 2019-01-31
SG11201705584VA (en) 2018-05-30
JP2022091748A (en) 2022-06-21
SG10201800265UA (en) 2018-02-27
JP2017226655A (en) 2017-12-28
TWI807666B (en) 2023-07-01
KR20190009273A (en) 2019-01-28

Similar Documents

Publication Publication Date Title
PE20190394A1 (en) ANTI-C5 ANTIBODIES AND METHODS OF USE
CL2020001974A1 (en) Anti-trem2 antibodies and methods of using them. (divisional request 201903093)
CL2019000668A1 (en) Antibodies against alpha regulatory signal protein and use procedures.
PE20171111A1 (en) ANTIMIOSTATIN ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT HR REGIONS, AND METHODS OF USE
SA518391704B1 (en) Anti-C5 Antibodies and Methods of Use
PH12017501114A1 (en) Anti-c5 antibodies and methods of use
AR122964A2 (en) PEPTIDES USEFUL IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER TYPES OF CANCER
CL2019003657A1 (en) Antibodies that specifically bind to cd38 useful for enhancing an immune response in a patient. (divisional request 201703275)
PE20200757A1 (en) AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND ITS USES
UY37928A (en) ANTI-CD38 ANTIBODIES AND METHODS OF USE
GT201700162A (en) ANTI-CD3 ANTIBODIES, ANTI-CD123 ANTIBODIES AND BIESPECIFIC ANTIBODIES THAT SPECIFICALLY JOIN CD3 AND / OR CD123
AR101846A1 (en) ANTI-CLL-1 ANTIBODIES AND IMMUNOCATE PLAYERS
CU24537B1 (en) MONOCLONAL ANTIBODIES COMPETING TO JOIN HUMAN TAU WITH THE 3D6 ANTIBODY
BR112013027829A2 (en) anti-cd40 antibodies and method of use
AR080914A1 (en) BETA-AMILOID UNION PROTEINS
CU20180135A7 (en) ISOLATED MONOCLONAL ANTIBODIES COMPETING FOR TAU UNION WITH ANTIBODY 3D6
ES2639026T3 (en) Totally human antibodies specific for CADM1
ES2722773T3 (en) Modified Meningococcal fHbp Polypeptides
MY193350A (en) Anti-vegf protein compositions and methods for producing the same
PE20191743A1 (en) BI-SPECIFIC ANTIBODIES ANTI-PD-L1-ANTI-TIM3
EA201690056A8 (en) ARTIFICIAL PROTEINS CONNECTING THE FACTOR N (fHbp), AND METHODS OF THEIR APPLICATION
CL2020002459A1 (en) C-terminal antibody variants
MX2022008298A (en) Antibody for skewing sex ratio and methods of use thereof.
AR100427A1 (en) PROTEINS OF UNION TO ANTIGEN OF HER1 THAT JOIN THE FORK b OF HER1
CO2022015049A2 (en) Autonomous knob domain peptides